A second, phase III study assessing MGB-BP-3 in the treatment of Clostridium-difficile-infections
Latest Information Update: 01 Feb 2021
At a glance
- Drugs MGB BP 3 (Primary) ; Vancomycin
- Indications Clostridium difficile infections
- Focus Registrational; Therapeutic Use
- Sponsors MGB Biopharma
- 01 Feb 2021 New trial record
- 27 Jan 2021 According to a MGB Biopharma media release, Professor Thomas Louie, clinical professor at the Cumming School of Medicine at the University of Alberta, Calgary (Canada) is a Principal Investigator.
- 27 Jan 2021 According to a MGB Biopharma media release, this phase III program will support the submission of a New Drug Application (NDA).